

## HLC029B – Table of Contents

Mar-08I

INTRODUCTION	XVI
STUDY GOALS AND OBJECTIVES	XVI
REASONS FOR DOING THIS STUDY	XVI
INTENDED AUDIENCE	XVII
SCOPE OF REPORT	XVII
INFORMATION SOURCES	XVIII
ANALYST CREDENTIALS	XVIII
RELATED REPORTS	XVIII
BCC ONLINE SERVICES	XVIII
DISCLAIMER	XIX
SUMMARY	XX
SUMMARY TABLE GLOBAL DIABETES MARKET FORECAST BY SEGMENT, THROUGH 2013 (\$ BILLIONS)	XXIII
SUMMARY FIGURE GLOBAL DIABETES MARKET FORECAST BY SEGMENT, 2006-2013 (\$ BILLIONS)	XXIII
OVERVIEW	1
OVERVIEW	1
TABLE 1 PREVALENCE OF TYPE I AND II DIABETES: TOP SIX COUNTRIES WITH HIGH GROWTH PROJECTIONS, THROUGH 2013 (MILLIONS)	2
TABLE 2 PREVALENCE OF TYPE II DIABETES: TOP SIX COUNTRIES WITH PROJECTIONS, THROUGH 2013 (MILLIONS)	3
TABLE 3 DEFINITIONS OF THE FOUR TYPES OF DIABETES	4
TABLE 3 (CONTINUED)	5
TABLE 4 SUMMARY OF DIABETES PRODUCTS AND APPLICATIONS	6
DIABETES DISEASE	7
CAUSATION, RISK FACTORS, AND COMPLICATIONS	7
TABLE 5 CAUSAL OR RISK FACTORS BY DIABETES TYPE	8
TABLE 6 COMPLICATIONS BY TYPE OF DIABETES	9
DIABETES MANAGEMENT	10
DIABETES MANAGEMENT (CONTINUED)	11
DIABETES MANAGEMENT (CONTINUED)	12
DIABETES PRODUCT SEGMENTS	13
CONTINUOUS GLUCOSE MONITORING SYSTEMS (CGMS)	13
CONTINUOUS GLUCOSE MONITORING ... (CONTINUED)	14
TABLE 7 FDA APPROVED CONTINUOUS GLUCOSE MONITORING SYSTEMS BY MANUFACTURER	15
INSULIN INFUSION PUMPS	16
TABLE 8 FDA APPROVED INSULIN INFUSION PUMPS BY MANUFACTURER	16
TABLE 9 PROJECTED MARKET LEADER SALES OF CONTINUOUS GLUCOSE MONITORING SYSTEMS AND INSULIN INFUSION PUMPS, THROUGH 2013 (\$ MILLIONS)	17

FIGURE 1 PROJECTED MARKET LEADER SALES OF CONTINUOUS GLUCOSE MONITORING SYSTEMS AND INSULIN INFUSION PUMPS, 2006-2013 (\$ MILLIONS)	18
INSULIN-DEPENDENT DRUGS	18
TABLE 10 TECHNOLOGICAL EVOLUTION OF INSULIN DELIVERY METHODS	19
TABLE 11 FDA APPROVED INSULIN-DEPENDENT PRODUCTS BY MARKET LEADER	20
INSULIN-DEPENDENT DRUGS (CONTINUED)	21
TABLE 12 INSULIN-DEPENDENT DRUG SALES FORECAST BY MANUFACTURER, THROUGH 2013 (\$ MILLIONS)	22
FIGURE 2 INSULIN-DEPENDENT DRUG SALES FORECAST BY MANUFACTURER, 2006-2013 (\$ MILLIONS)	22
INSULIN-INDEPENDENT DRUGS	23
TABLE 13 THE SEVEN CLASSES OF TYPE II DIABETES DRUGS	24
TABLE 13 (CONTINUED)	25
SULFONYLUREAS	25
TABLE 14 FDA APPROVED BRAND-NAME SULFONYLUREA DRUGS BY DRUGMAKER	26
TABLE 14 (CONTINUED)	27
BIGUANIDES	27
TABLE 15 FDA APPROVED BRAND-NAME BIGUANIDE DRUGS	28
ALPHA-GLUCOSIDASE INHIBITORS	28
TABLE 16 FDA APPROVED BRAND-NAME ALPHA-GLUCOSIDASE INHIBITOR DRUGS	29
MEGLITINIDES	29
TABLE 17 FDA APPROVED BRAND-NAME MEGLITINIDE DRUGS	29
THIAZOLIDINEDIONES (TZD)	30
TABLE 18 FDA APPROVED BRAND-NAME THIAZOLIDINEDIONES DRUGS	30
INCRETIN MIMETICS	31
TABLE 19 FDA APPROVED BRAND-NAME INCRETIN MIMETICS DRUGS	32
DIPEPTIDYL PEPTIDASE 4 (DPP-4)	32
TABLE 20 FDA APPROVED BRAND-NAME DPP-4 DRUGS	32
TABLE 21 TOP SELLING BRAND-NAME INSULIN-INDEPENDENT DRUG FORECAST, THROUGH 2013 (\$ MILLIONS)	33
FIGURE 3 TOP SELLING BRAND-NAME INSULIN-INDEPENDENT DRUG FORECAST, 2006-2013 (\$ MILLIONS)	33
SURGICAL TREATMENT OF DIABETES	33
TABLE 22 THE MARKET FOR NEW CLASSES OF DIABETES TREATMENTS	34
DIABETIC COMPLICATIONS MARKET	35
RETINOPATHY (EYE DISEASE)	35
NEUROPATHY (NERVE DISEASE)	36
NEPHROPATHY (KIDNEY DISEASE)	36

ARTERIOSCLEROSIS (CARDIOVASCULAR DISEASE)	36
OTHER COMPLICATIONS	37
PRESCRIPTION DRUGS FOR DIABETES COMPLICATIONS	38
CHOLESTEROL DRUGS	39
Torcetrapib (Pfizer)	39
HYPERTENSION DRUGS	39
Exforge (Novartis)	39
Tekturna (Novartis)	39
CORONARY INTERVENTION	40
Effient (Eli Lilly/Daiichi Sankyo)	40
TABLE 23 DRUGS USED TO TREAT COMMON DIABETIC COMPLICATIONS, BY MANUFACTURER	40
TABLE 24 FORECAST OF TOP SELLING DRUGS USED IN THE TREATMENT OF COMMON DIABETIC COMPLICATIONS BY MANUFACTURER, THROUGH 2013 (\$ MILLIONS)	41
FIGURE 4 FORECAST OF TOP SELLING DRUGS USED IN THE TREATMENT OF COMMON DIABETIC COMPLICATIONS BY MANUFACTURER, 2006–2013 (\$ MILLIONS)	42
GENERIC ANTIDIABETIC DRUG MARKET	43
GENERIC ANTIDIABETIC DRUG MARKET	43
TABLE 25 FDA APPROVED GENERIC SULFONYLUREAS BY MANUFACTURER	44
TABLE 25 (CONTINUED)	45
TABLE 26 FDA APPROVED GENERIC BIGUANIDES BY MANUFACTURER	45
TABLE 27 FDA APPROVED GENERIC MEGLITINIDES BY MANUFACTURER	46
TABLE 28 FDA APPROVED GENERIC THIAZOLIDINEDIONES, BY MANUFACTURER	46
TABLE 29 TOP SELLING GENERIC ANTIDIABETIC DRUG FORECAST, THROUGH 2013 (\$ MILLIONS)	47
DIABETES DRUGS IN DEVELOPMENT	48
CLINICAL TRIALS PHASES I–IV	48
PHASE I CLINICAL TRIALS ON DIABETES DRUGS	49
TABLE 30 DIABETES DRUGS IN PHASE I CLINICAL TRIALS	50
PHASE II CLINICAL TRIALS ON DIABETES DRUGS	50
TABLE 31 DIABETES DRUGS IN PHASE II CLINICAL TRIALS	51
PHASE III CLINICAL TRIALS ON DIABETES DRUGS	51
TABLE 32 DIABETES DRUGS IN PHASE III CLINICAL TRIALS	52
PHASE IV CLINICAL TRIALS ON DIABETES DRUGS	52
TABLE 33 DIABETES DRUGS IN PHASE IV CLINICAL TRIALS	53
COMPLETED CLINICAL TRIALS ON TYPE I DIABETES DRUGS	53
TABLE 34 COMPLETED CLINICAL TRIALS ON TYPE I DIABETES DRUGS	53
COMPLETED CLINICAL TRIALS ON TYPE II DIABETES DRUGS	53

TABLE 35 COMPLETED CLINICAL TRIALS ON TYPE II DIABETES DRUGS	
53	
COMPLETED CLINICAL TRIALS ON DRUGS USED TO TREAT BOTH TYPES OF DIABETES	54
TABLE 36 COMPLETED CLINICAL TRIALS ON DRUGS USED TO TREAT BOTH TYPE I AND TYPE II DIABETES	54
PHASE I CLINICAL TRIALS ON TREATMENTS FOR DIABETES COMPLICATIONS	54
TABLE 37 PHASE I CLINICAL TRIALS ON DRUGS USED TO TREAT COMMON DIABETIC COMPLICATIONS	54
PHASE II CLINICAL TRIALS ON TREATMENTS FOR DIABETES COMPLICATIONS	55
TABLE 38 PHASE II CLINICAL TRIALS ON DRUGS USED TO TREAT COMMON DIABETIC COMPLICATIONS	55
PHASE III CLINICAL TRIALS ON TREATMENTS FOR DIABETES COMPLICATIONS	55
TABLE 39 PHASE III CLINICAL TRIALS ON DRUGS USED TO TREAT COMMON DIABETIC COMPLICATIONS	56
PHASE IV CLINICAL TRIALS ON TREATMENTS FOR DIABETES COMPLICATIONS	56
TABLE 40 PHASE IV CLINICAL TRIALS ON DRUGS USED TO TREAT COMMON DIABETIC COMPLICATIONS	56
COMPLETED CLINICAL TRIALS ON DRUGS USED TO TREAT COMMON DIABETIC COMPLICATIONS	57
TABLE 41 COMPLETED CLINICAL TRIALS ON DRUGS USED TO TREAT COMMON DIABETIC COMPLICATIONS	57
INCRETIN MIMETICS	57
PRAMLINTIDE	58
EXENATIDE	58
LIRAGLUTIDE (PHASE III)	58
DPP-4 INHIBITORS	58
VILDAGLIPTIN	58
SITAGLIPTIN	59
GLITAZARS (DUAL-PPAR AGONISTS)	59
MURAGLITAZAR	59
PATENT ANALYSIS OF DIAGNOSTIC AND THERAPEUTIC DIABETES TREATMENTS	60
TABLE 42 WORLDWIDE SHARES OF PATENTS AND PUBLISHED PATENT APPLICATIONS ON TYPE I AND TYPE II DIABETES TREATMENTS BY SELECTED COUNTRY, 1/1/2001–11/1/2007 (NUMBER)	60
U.S. AND EUROPEAN PATENTS ON TYPE I DIABETES TREATMENTS	61
TABLE 43 U.S. AND EUROPEAN SHARES OF PATENTS ON TYPE I DIABETES TREATMENTS BY PATENT HOLDER, 1/1/1991–11/30/2007 (NUMBER)	61
U.S. AND EUROPEAN PATENTS ON TYPE II DIABETES TREATMENTS	62
TABLE 44 U.S. AND EUROPEAN SHARES OF PATENTS ON TYPE II DIABETES TREATMENTS BY PATENT HOLDER, 1/1/1991 TO 11/30/2007 (NUMBER)	62

TABLE 45	WORLDWIDE SHARES OF PATENTS AND PATENT APPLICATIONS ON INCRETIN MIMETICS AND DPP-4 INHIBITORS BY PATENT HOLDER, 1/1/2001–11/1/2007 (NUMBER)	63
TABLE 46	U.S. AND EUROPEAN SHARES OF PATENTS ON INCRETIN MIMETICS AND DPP-4 INHIBITORS BY PATENT HOLDER, 1/1/1991–11/30/2007 (NUMBER)	63
TABLE 47	WORLDWIDE SHARES OF PATENTS AND PATENT APPLICATIONS ON SITAGLIPTIN BY PATENT HOLDER, 1/1/2001–11/1/2007 (NUMBER)	64
TABLE 48	WORLDWIDE SHARES OF PATENTS AND PATENT APPLICATIONS ON VILDAGLIPTIN BY PATENT HOLDER, 1/1/2001–11/1/2007 (NUMBER)	64
TABLE 49	U.S. PATENT SHARES OF VILDAGLIPTIN BY PATENT HOLDER, 1/1/1991–11/30/2007 (NUMBER)	64
TABLE 50	WORLDWIDE SHARES OF PATENTS AND PATENT APPLICATIONS ON SAXAGLIPTIN BY PATENT HOLDER, 1/1/2001–11/1/2007 (NUMBER)	65
TABLE 51	U.S. PATENT SHARES OF LIRAGLUTIDE BY PATENT HOLDER, 1/1/1991–11/30/2007 (NUMBER)	65
TABLE 52	WORLDWIDE SHARES OF PATENTS AND PATENT APPLICATIONS ON TESAGLITAZAR BY PATENT HOLDER, 1/1/2001–11/1/2007 (NUMBER)	65
TABLE 53	WORLDWIDE SHARES OF PATENTS AND PATENT APPLICATIONS ON MURAGLITAZAR BY PATENT HOLDER, 1/1/2001–11/1/2007 (NUMBER)	66
	U.S. AND EUROPEAN PATENTS ON INSULIN DELIVERY OTHER THAN SUBCUTANEOUS METHODS	66
TABLE 54	U.S. AND EUROPEAN SHARES OF PATENTS ON INSULIN DELIVERY OTHER THAN SUBCUTANEOUS METHODS, 1/1/1991–11/30/2007 (NUMBER)	66
	U.S. AND EUROPEAN PATENTS ON INSULIN INFUSION PUMPS	67
TABLE 55	U.S. AND EUROPEAN SHARES OF PATENTS ON INSULIN INFUSION PUMPS BY PATENT HOLDER, 1/1/1991–11/30/2007 (NUMBER)	67
	U.S. AND EUROPEAN PATENTS ON CONTINUOUS GLUCOSE MONITORING SYSTEMS	67
TABLE 56	U.S. AND EUROPEAN SHARES OF PATENTS ON CONTINUOUS GLUCOSE MONITORING SYSTEMS BY PATENT HOLDER, 1/1/1991–11/30/2007 (NUMBER)	67
TABLE 57	U.S. AND EUROPEAN SHARES OF PATENTS ON BLOOD GLUCOSE METERS BY PATENT HOLDER, 1/1/1991–11/30/2007 (NUMBER)	68
	INSULIN INHALER MARKET	69
	DRUGMAKERS DEVELOPING INHALABLE INSULIN	69
	PFIZER	69
	ABBOTT LABORATORIES AND KOS PHARMACEUTICALS	69
	ELI LILLY & CO. AND ALKERMES	70
	MANNKIND CORP.	71
	NOVO NORDISK AND ARADIGM	72
	BAXTER INTERNATIONAL	73

NASTECH PHARMACEUTICAL CO.	73
GENEREX BIOTECHNOLOGY	73
TABLE 58 INHALED INSULIN PRODUCTS UNDER DEVELOPMENT BY COMPANY	74
INSULIN INFUSION PUMP MARKET	75
INSULIN INFUSION PUMP MARKET	75
INSULIN INFUSION PUMP MARKET (CONTINUED)	76
INSULIN INFUSION PUMP MARKET (CONTINUED)	77
INSULIN INFUSION PUMP MARKET (CONTINUED)	78
INSULIN DISPENSING PATCH MARKET	79
INSULIN DISPENSING PATCH MARKET	79
TABLE 59 INSULIN DISPENSING PATCHES BY MANUFACTURER	80
COMPANY PROFILES	81
ABBOTT LABORATORIES, INC.	81
ABBOTT DIABETES CARE, INC.	81
ACTAVIS	82
ACTAVIS U.S.	83
ALIZYME, PLC	83
ALKERMES INC.	83
ALKERMES INC. (CONTINUED)	84
AMYLIN PHARMACEUTICALS, INC.	85
ARADIGM CORP.	86
ASTELLA PHARMACEUTICALS	87
ASTRAZENECA, PLC	87
ASTRAZENECA U.S.	87
AstraZeneca U.S. (Continued)	88
BARR PHARMACEUTICALS, INC.	89
BARR PHARMACEUTICALS, INC. (CONTINUED)	90
BAYER SCHERING PHARMA AG	91
BAYER HEALTHCARE PHARMACEUTICALS U.S.	91
BAYER GLOBAL HEALTHCARE DIABETES CARE	92
Bayer Global HealthCare Diabetes Care (Continued)	93
Bayer Global HealthCare Diabetes Care (Continued)	94
BRISTOL-MYERS SQUIBB CO.	95
BRISTOL-MYERS SQUIBB CO. (CONTINUED)	96
CARACO PHARMA LABS, LTD.	97
DAIICHI-SANKYO, LTD.	98
DAIICHI-SANKYO, INC.	98
Daiichi-Sankyo, Inc. (Continued)	99
DEBIOTECH	100
DEPOMED, INC.	101
DEPOMED, INC. (CONTINUED)	102
DEXCOM	103
DR. REDDY'S LABORATORIES, LTD.	103
DR. REDDY'S LABORATORIES, LTD.	103
ELI LILLY & CO.	104

ELI LILLY & CO. (CONTINUED)	105
ELI LILLY & CO. (CONTINUED)	106
ELI LILLY & CO. (CONTINUED)	107
GLAXOSMITHKLINE, PLC	108
GLAXOSMITHKLINE	108
INSULET CORP.	109
JOHNSON & JOHNSON CO.	110
LIFESCAN, INC.	110
KERYX BIOPHARMACEUTICALS INC.	111
MANNKIND CORP.	112
MANNKIND CORP. (CONTINUED)	113
MEDTRONIC INC.	114
MEDTRONIC DIABETES	114
Medtronic Diabetes (Continued)	115
MERCK & CO., INC.	116
MERCK & CO., INC. (CONTINUED)	117
MYLAN, INC.	118
NOVARTIS AG	119
NOVARTIS U.S.	119
Novartis U.S. (Continued)	120
NOVO NORDISK A/S	121
NOVO NORDISK U.S.	121
Novo Nordisk U.S. (Continued)	122
PAR PHARMACEUTICAL COMPANIES, INC.	123
PFIZER, INC.	124
RANBAXY LABORATORIES, INC.	125
RANBAXY U.S.	125
ROCHE DIAGNOSTICS CORP.	126
SANDOZ (NOVARTIS GENERIC DIVISION)	127
SANDOZ U.S.	127
SANOFI-AVENTIS A.G.	127
SANOFI-AVENTIS U.S., LLC	127
Sanofi-Aventis U.S., LLC (Continued)	128
SANTHERA PHARMACEUTICALS	129
SMITHS MEDICAL	130
SMITHS MEDICAL ASD, INC.	130
TAKEDA PHARMACEUTICAL CO., LTD.	131
TEVA PHARMACEUTICALS, INC.	132
TEVA PHARMACEUTICALS USA	133
WATSON LABORATORIES, INC.	134
WYETH	135
WYETH (CONTINUED)	136